BIO selects presenting companies for investor forum.
Share:
Press Release Summary:
BIO announced initial selection of presenting companies, chosen through screening process with input by advisory committee, for 8th Annual BIO Investor Forum on October 28-29. Forum will feature over 110 company presentations. It will host panels for industry leaders; feature plenary sessions on sustaining biotech innovation in light of healthcare reform; and forecast key industry and investment catalysts for 2010. Therapeutic workshops and business roundtables will also be included.
Original Press Release:
BIO Announces Selection of 2009 Presenting Companies for 8th Annual BIO Investor Forum
Industry Leaders to Discuss Investment Opportunities and Approaches to Sustaining and Leveraging Innovation
WASHINGTON, D.C. (Tuesday, September 01, 2009) - The Biotechnology Industry Organization (BIO) today announced the initial selection of 2009 presenting companies for the 8th Annual BIO Investor Forum on October 28-29 at the Palace Hotel in San Francisco, Calif. Companies identified to speak at this conference represent some of the most innovative therapeutic advances in the biotechnology sector.
The BIO Investor Forum will feature over 110 company presentations from select late-stage private and emerging public biotech companies. Companies were chosen through a competitive screening process with input by an advisory committee comprised of members from top-tier firms focused on investing and banking in the life sciences industry. The advisory committee includes:
o Benjamin R. Bowen, Ph.D., Rodman & Renshaw, LLC
o Howard Furst, M.D., Deerfield Management
o John R. Leone, Paul Capital
o Graeme Martin, Ph.D., Takeda Research Investments, Inc.
o Evan McCulloch, CFA, Franklin Templeton Investments
o Oleg Nodelman, Biotechnology Value Fund, LP
o Heather Preston, M.D., TPG Biotech
o Bryan E. Roberts, Ph.D., Venrock
o Mark Schoenebaum, M.D., Deutsche Bank AG
o Chris Swindle, Wedbush PacGrow Life Sciences
o Paul Wagner, Ph.D., CFA, RCM Capital Management, LLC
"The BIO Investor Forum will feature senior management from biotech companies that are poised for leadership status in highly competitive areas of therapeutic innovation," said Alan Eisenberg, executive vice president, Emerging Companies & Business Development at BIO. "The companies selected to speak in 2009 are creating value through development-stage programs with near-term clinical catalysts. `These are the companies that will help drive the investment and deal making in the life sciences sector and global innovation in healthcare."
The following companies will present at the 8th Annual BIO Investor Forum:
Acologix, Inc.
Advanced Life Sciences (ADLS)
Advaxis Inc. (ADXS)
Affectis Pharmaceuticals AG
Alchemia Ltd. (ACL)
Allon Therapeutics Inc. (NPC)
Amira Pharmaceuticals, Inc.
Anadys Pharmaceuticals Inc. (ANDS)
Aradigm Corporation (ARDM)
Arete Therapeutics
Athersys Inc. (ATHX)
Bayhill Therapeutics, Inc.
BioSante Pharmaceuticals, Inc. (BPAX)
Biotec Pharmacon ASA (BIOTEC)
BrainCells, Inc.
Calistoga Pharmaceuticals
Catalyst Biosciences, Inc.
Celladon
Ceregene, Inc.
Chimerix, Inc.
Cleveland BioLabs Inc. (CBLI)
CoLucid Pharmaceuticals
Complete Genomics, Inc.
Curis, Inc. (CRIS)
Cyclacel Pharmaceuticals Inc. (CYCC)
Cylene Pharmaceuticals, Inc.
EGEN, Inc.
Elixir Pharmaceuticals, Inc.
Endocyte, Inc.
Epeius Biotechnologies Corp.
Essentialis, Inc.
ExonHit Therapeutics S.A. (ALEHT)
GenVec, Inc. (GNVC)
GlobeImmune, Inc.
ImmunoVaccine Technologies Inc.
ImmuPharma plc (IMM)
Inimex Pharmaceuticals, Inc.
Inotek Pharmaceuticals Corp.
Inovio Biomedical Corp. (INO)
Intarcia Therapeutics, Inc.
Intrexon Corporation
KAI Pharmaceuticals, Inc.
LifeCycle Pharma A/S (LCP)
LigoCyte Pharmaceuticals, Inc.
Locus Pharmaceuticals, Inc.
MacroGenics, Inc.
Marinus Pharmaceuticals, Inc.
MDRNA, Inc. (MRNA)
MethylGene Inc. (MYG)
Micromet Inc. (MITI)
NeurAxon Inc.
Newron Pharmaceuticals S.p.A. (NWRN)
NovaBay Pharmaceuticals Inc. (NBY)
Novalar Pharmaceuticals, Inc.
Novavax, Inc. (NVAX)
Novelos Therapeutics Inc. (NVLT)
Nuon Therapeutics, Inc.
Oncolytics Biotech Inc. (ONCY)
OncoMed Pharmaceuticals, Inc.
Osteologix Inc. (OLGX)
ParinGenix, Inc.
Peptimmune, Inc.
Plexxikon Inc.
Portola Pharmaceuticals, Inc.
Presidio Pharmaceuticals, Inc.
Profectus Biosciences, Inc.
PTC Therapeutics
QuatRx Pharmaceuticals
Raptor Pharmaceuticals Corp. (RPTP)
Regado Biosciences, Inc.
Resolvyx Pharmaceuticals, Inc.
SARcode Corporation
Somaxon Pharmaceuticals, Inc. (SOMX)
Stromedix, Inc.
Supernus Pharmaceuticals, Inc.
Targacept, Inc. (TRGT)
Transcept Pharmaceuticals, Inc. (TSPT)
Tranzyme Pharma, Inc.
Trubion Pharmaceuticals Inc. (TRBN)
VirtualScopics, Inc. (VSCP)
VLST Corporation, Inc.
WaferGen Bio-Systems Inc. (WGBS)
Wilex AG (WL6)
Zelos Therapeutics, Inc.
ZIOPHARM Oncology Inc. (ZIOP)
The BIO Investor Forum will also host panels for industry leaders to weigh strategies for efficient product development, evaluating therapeutic investment and accessing capital and resources. Highlights for this year's conference include plenary sessions on sustaining biotech innovation in light of healthcare reform, as well as forecasting key industry and investment catalysts for 2010. Therapeutic workshops will address areas of dynamic pipeline growth including prostate cancer, influenza, autoimmune disease and personalized medicine; and this year's business roundtables will offer the buyer's perspective on today's IPO candidates and prospects, the insider's view on designing clinical trials that increase deal value, and new deal structures designed to reduce M&A risk.
The BIO Investor Forum is a national investor conference featuring leading private and emerging public companies. The meeting attracts sophisticated healthcare venture capital and public market investors and research analysts. In addition, the BIO Investor Forum draws business development executives from leading global pharmaceutical and biotechnology companies.
To learn more about the BIO Investor Forum, including registration and program information, please visit investorforum.bio.org/. Registration is complimentary for qualified investors.
BIO Investor Forum
October 28-29, 2009
San Francisco, CA
Advanced Business Development Course
October 30, 2009
Vienna, Austria
BIO Europe International Partnering Conference
November 2-4, 2009
Vienna, Austria
Pacific Rim Summit on Industrial Biotechnology and Bioenergy
November 8-11, 2009
Honolulu, HI
About BIO
BIO represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.
Contact:
Erin Reese
202-962-9235
